Flag­ship bankrolls quest to cre­ate gene ther­a­py 2.0, with new vi­ral de­liv­ery tech in hand

Count Flag­ship Pi­o­neer­ing in for the long and con­vo­lut­ed chase of new de­liv­ery ve­hi­cles that promise to ex­pand the boom­ing gene ther­a­py field.

Ring Ther­a­peu­tics, its lat­est biotech cre­ation, has a $50 mil­lion com­mit­ment to ex­plore anellovec­tors — a whole new class of vi­ral shells that it claims of­fers the first “re­al al­ter­na­tive” to ade­n­ovirus-as­so­ci­at­ed virus­es, or AAV, ap­proach­es. If proved vi­able, that could open up a whole new fron­tier in­to dis­eases that are cur­rent­ly off lim­its to gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER